Citation Impact
Citing Papers
4-Hydroxynonenal, an endogenous aldehyde, causes pain and neurogenic inflammation through activation of the irritant receptor TRPA1
2007 StandoutNobel
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
2013 StandoutScienceNobel
Pharmacologic Targeting of Hypoxia-Inducible Factors
2019 StandoutNobel
Expansive discovery of chemically diverse structured macrocyclic oligoamides
2024 StandoutScienceNobel
Hypoxia-inducible factor 2α (HIF-2α) heterozygous-null mice exhibit exaggerated carotid body sensitivity to hypoxia, breathing instability, and hypertension
2011 StandoutNobel
Genome-wide Association of Hypoxia-inducible Factor (HIF)-1α and HIF-2α DNA Binding with Expression Profiling of Hypoxia-inducible Transcripts
2009 StandoutNobel
Regulation of Type II Transmembrane Serine Proteinase TMPRSS6 by Hypoxia-inducible Factors
2010 StandoutNobel
Hypoxia-Inducible Factors in Physiology and Medicine
2012 StandoutNobel
Tuning the Transcriptional Response to Hypoxia by Inhibiting Hypoxia-inducible Factor (HIF) Prolyl and Asparaginyl Hydroxylases
2016 StandoutNobel
AGEs and Diabetic Retinopathy
2010
Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases
2016 StandoutNobel
Diabetic retinopathy
2010 Standout
Estimating phosphate removal in haemodialysis: an additional tool to quantify dialysis dose
2002
Sirtuin-7 Inhibits the Activity of Hypoxia-inducible Factors
2013 StandoutNobel
Acute Kidney Injury and Chronic Kidney Disease as Interconnected Syndromes
2014 Standout
The Role of Advanced Glycation End Products in Progression and Complications of Diabetes
2008
Regulation of immunity and inflammation by hypoxia in immunological niches
2017
Intervention strategies to inhibit protein carbonylation by lipoxidation‐derived reactive carbonyls
2006
The bone marrow niche for haematopoietic stem cells
2014 StandoutNature
HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond
2015
Role of the N-terminal Catalytic Domain of Angiotensin-converting Enzyme Investigated by Targeted Inactivation in Mice
2004 StandoutNobel
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
Hypoxia drives glucose transporter 3 expression through hypoxia-inducible transcription factor (HIF)–mediated induction of the long noncoding RNA NICI
2019 StandoutNobel
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Does Accumulation of Advanced Glycation End Products Contribute to the Aging Phenotype?
2010
Four-and-a-Half LIM Domain Proteins Inhibit Transactivation by Hypoxia-inducible Factor 1
2012 StandoutNobel
Neurodegeneration and Inflammation
2008
Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
2016 StandoutNobel
HIF-1α Is Essential for Myeloid Cell-Mediated Inflammation
2003 Standout
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
From endoplasmic-reticulum stress to the inflammatory response
2008 StandoutNature
Emerging drugs for diabetic retinopathy
2008
Diabetes and advanced glycation endproducts
2002
Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1α
1999 StandoutNobel
Hsp70 and CHIP Selectively Mediate Ubiquitination and Degradation of Hypoxia-inducible Factor (HIF)-1α but Not HIF-2α
2009 StandoutNobel
Correction of Anemia with Epoetin Alfa in Chronic Kidney Disease
2006 Standout
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia
2014
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients
2015
Impact of epoetin alfa on clinical end points in patients with chronic renal failure: A meta-analysis
2004
Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1α
1998 StandoutNobel
Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
2017 Standout
Dose of Erythropoiesis-Stimulating Agents and Adverse Outcomes in CKD: A Metaregression Analysis
2012
Frailty in elderly people
2013 Standout
Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
2019
Trends in peptide drug discovery
2021
Lack of angiotensin II–facilitated erythropoiesis causes anemia in angiotensin-converting enzyme–deficient mice
2000 StandoutNobel
Chaperone-mediated Autophagy Targets Hypoxia-inducible Factor-1α (HIF-1α) for Lysosomal Degradation
2013 StandoutNobel
Angiopoietin-like 4 is a potent angiogenic factor and a novel therapeutic target for patients with proliferative diabetic retinopathy
2015 StandoutNobel
Diabetic Nephropathy: Diagnosis, Prevention, and Treatment
2005 Standout
General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia.
1993 StandoutNobel
Clinical iron deficiency disturbs normal human responses to hypoxia
2016 StandoutNobel
Advanced Glycation End Products
2006 Standout
Physiology meets biophysics: Visualizing the interaction of hypoxia-inducible factor 1α with p300 and CBP
2002 StandoutNobel
The Tumor Lysis Syndrome
2011 Standout
Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes
2005 Standout
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Single-nanometer iron oxide nanoparticles as tissue-permeable MRI contrast agents
2021 StandoutNobel
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
2020 Standout
Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury
2010
Oxygen-regulated control elements in the phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the erythropoietin 3' enhancer.
1994 StandoutNobel
Advanced glycation and retinal pathology during diabetes.
2005
Efficacy and safety of IV ferumoxytol for adults with iron deficiency anemia previously unresponsive to or unable to tolerate oral iron
2013
Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth
1997 StandoutNobel
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Iron-Deficiency Anemia
2015 Standout
BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
2018 StandoutNobel
Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression
2012 StandoutNobel
Superparamagnetic Iron Oxide Nanoparticles: Diagnostic Magnetic Resonance Imaging and Potential Therapeutic Applications in Neurooncology and Central Nervous System Inflammatory Pathologies, a Review
2009
Clinical Use of Intravenous Iron: Administration, Efficacy, and Safety
2010
Exceedingly small iron oxide nanoparticles as positive MRI contrast agents
2017 StandoutNobel
Glycation and Carboxymethyllysine Levels in Skin Collagen Predict the Risk of Future 10-Year Progression of Diabetic Retinopathy and Nephropathy in the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications Participants With Type 1 Diabetes
2005
Clinical Translation of Nanomedicine
2015
Ferumoxytol for the treatment of iron deficiency anemia
2018
Works of Bruce Spinowitz being referenced
Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease
2016
Ferumoxytol for Treating Iron Deficiency Anemia in CKD
2008
Randomized Trial of an Inhibitor of Formation of Advanced Glycation End Products in Diabetic Nephropathy
2004
Fractional direct dialysis quantification: A new approach for prescription and monitoring hemodialysis therapy
1996
The safety and efficacy of ferumoxytol therapy in anemic chronic kidney disease patients
2005
A Randomized Study of Extended Dosing Regimens for Initiation of Epoetin Alfa Treatment for Anemia of Chronic Kidney Disease
2008
Peginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving Dialysis
2013
Effect of Angiotensin-Converting Enzyme Inhibitors on Response to Erythropoietin Therapy in Chronic Dialysis Patients
1998
Safety of Iron Sucrose in Hemodialysis Patients Intolerant to Other Parenteral Iron Products
2004
Effect of Sodium Zirconium Cyclosilicate on Potassium Lowering for 28 Days Among Outpatients With Hyperkalemia
2014